Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines emerging and past therapies for recurrent implantation failure, focusing on three innovative strategies: PBMC, G-CSF, and PRP, but reports no new clinical results.

Lichen planopilaris and frontal fibrosing alopecia are likely distinct diseases with different tissue involvement.

This study found that Pik3r1 Y657* mice, which model human SHORT syndrome, show increased energy expenditure despite insulin resistance, but this is not due to changes in locomotion, thermoregulation, or Ucp1-dependent thermogenesis, suggesting a different metabolic mechanism may protect against lipotoxicity.

This research abstract provides information about the publisher, Wolters Kluwer Health, and the journal's subscription services, but it doesn’t describe a specific study or research findings. Results are not reported.

This bibliometric analysis of the IP Indian Journal of Clinical and Experimental Dermatology reveals a steady annual publication growth rate of 5.49% from 2019 to 2025, moderate citation impact, and limited international collaboration.

This study found that immune privilege collapse in the hair follicle bulge and associated immune responses may contribute significantly to the pathogenesis of lichen planopilaris, suggesting a potential autoimmune basis for the disease.

This study identified CYP3A4 as a key isozyme involved in the oxidative metabolism of finasteride in human liver microsomes.

This study found diverse clinical presentations of lichen planopilaris, with classic lichen planopilaris being the most common, highlighting the importance of recognizing this variability for accurate diagnosis.

This article examines the PCPT study on whether daily finasteride can reduce prostate cancer incidence, describing its methodology and findings but reporting no new clinical results.

In in-vitro experiments, this study found that poncirin showed higher inhibitory activity against JAK3 than tofacitinib, suggesting potential for alopecia areata treatment.

In this study, researchers demonstrated that treating platelet rich plasma with microsecond pulsed electric fields effectively activates platelets and induces similar or higher growth factor release compared to traditional bovine thrombin, suggesting a potential clinical use that may be more cost-effective and practical.

This article discusses platelet-rich plasma therapy for cicatricial alopecias like lichen planopilaris and reports no confirmed new clinical results; the authors highlight ongoing uncertainty about its effectiveness and potential risks.

In this study, 15d-PGJ2 administered in a topical cream inhibited oxidative and inflammatory skin changes caused by UVB radiation in hairless mice, suggesting it as a promising treatment approach.

This study observed that people with autoimmune blistering skin disorders report higher food intolerance rates, particularly avoiding alcohol, citrus, and spicy foods, and suggests potential dietary influences on symptom management.

This study found that PRL-1-overexpressing PD-MSCs reduced adipogenesis in orbital fibroblasts from Graves' ophthalmopathy patients by secreting IGFBPs and modulating the FAK pathway.

This case report describes a patient who experienced proton-induced alopecia after proton therapy for a frontal meningioma, which was effectively treated with topical minoxidil, resulting in full hair regrowth after 4 months.

This case report by the researchers observed a complete remission of lichen planopilaris in a 58-year-old woman after treatment with the JAK-1 inhibitor abrocitinib, although they noted that concurrent topical therapy might have contributed to this outcome.

This study observed that fibrin rich in leukocytes and platelets (L-PRF) might effectively heal diabetic foot ulcers with osteomyelitis, showing positive preliminary results in all three patients treated.

In this study, researchers identified a recurrent MBTPS2 splice-site variant as a mutational hotspot in IFAP syndrome across diverse families, with phenotype severity suggesting the influence of additional modifiers.

Among patients with biopsy-proven FAPD in specialized hair clinics, this study found the condition is common in females around 52.5 years old, with treatment generally stabilizing or slightly improving hair loss, despite challenges in differentiating FAPD from androgenetic alopecia.

Frontal fibrosing alopecia can occur with lichen planus pigmentosus, needing careful diagnosis and treatment.

This commentary reviews the evidence for microinflammation's role in pattern hair loss and suggests that further studies with age- and sex-matched controls are needed to substantiate the findings.

This article reviews treatments for progeria, including aspirin, hydrotherapy, and farnesyl transferase inhibitors, but reports no new clinical results.

This review examines the clinicopathologic features of perifollicular elastolysis and indicates that, while its presentation is consistent, there is a lack of high-certainty evidence for effective treatments.

This study reports that a new mouse model with a CARD14 mutation successfully mimics key human PRP symptoms, and anti-IL-17A antibody significantly reduces these symptoms.

In this report, a 35-year-old female with palmoplantar pustulosis undergoing secukinumab treatment developed alopecia areata, a rare side effect attributed to paradoxical reactions with IL-17 inhibitors; switching to tofacitinib improved both conditions.

The researchers reported a case where treatment with tofacitinib improved both hair loss and skin lesions in a patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa over six months, with no recurrence or adverse events during two-year follow-up.

This study identified the Itpr3 gene as responsible for the tufted hair loss phenotype in the BTBR mouse strain.

This study suggests that IL-1β may play a role in inflammatory signaling pathways in papulopustular rosacea, contributing to its pathogenesis.

This study found that tofacitinib may be effective for treating pediatric rheumatic diseases, with especially promising results in patients with autoinflammatory diseases, arthritis and alopecia, and juvenile dermatomyositis.